Cas:84292-45-5 4-(5-methyltriazol-1-yl)aniline manufacturer & supplier

We serve Chemical Name:4-(5-methyltriazol-1-yl)aniline CAS:84292-45-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(5-methyltriazol-1-yl)aniline

Chemical Name:4-(5-methyltriazol-1-yl)aniline
CAS.NO:84292-45-5
Synonyms:f3375-2005
Molecular Formula:C9H10N4
Molecular Weight:174.20200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:56.73000
Exact Mass:174.09100
LogP:1.73910

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like f3375-2005 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,f3375-2005 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,f3375-2005 Use and application,f3375-2005 technical grade,usp/ep/jp grade.


Related News: Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days. 4-(5-methyltriazol-1-yl)aniline manufacturer The firm also has several lawyers whose reputations would carry weight with the Justice Department and the FDA, including former Attorney General Eric Holder, legal experts said. Gerald Masoudi, the Covington partner who handled the recent inquiry for Lilly, once served as the FDA’s chief counsel. Masoudi did not respond to requests for comment. 4-(5-methyltriazol-1-yl)aniline supplier Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days. 4-(5-methyltriazol-1-yl)aniline vendor Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days. 4-(5-methyltriazol-1-yl)aniline factory There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.